Patients may experience an improvement in symptoms with advancing age, although a complete remission actually is a really uncommon phenomenon.
3 However, available treatment options are not disease modifying and NT1 is usually considered as a non-remitting chronic disease with a variable course over the years.
2 Pharmacological treatment of patients with NT1 relies mainly on stimulant and anti-cataplectic drugs. The main clinical features are severe, and include irresistible excessive daytime sleepiness (EDS), cataplexy, sleep hallucinations, sleep paralysis and fragmented nocturnal sleep. 1 NT1 is associated with a variety of sleep and wake symptoms. Narcolepsy type 1 (NT1) is considered to be a rare, lifelong neurological disorder related to selective loss of lateral hypothalamic orexin neurons due to a possible autoimmune process. Keywords: narcolepsy, cataplexy, excessive daytime sleepiness, orexin, hypocretin, remission However, spontaneous remission of disease occurred after 15 years.
During the first years after disease onset, the patient did not show any significant improvement despite treatment with a variety of stimulant and anti-cataplectic drugs. Université de Paris, NeuroDiderot, Inserm, Paris, F-75019, FranceĪbstract: We describe the case of a male patient who was diagnosed with narcolepsy type 1 on the basis of sleep and wake symptoms, and the results of investigations including video-polysomnography, multiple sleep latency test, human leukocyte antigen status and orexin level in cerebrospinal fluid. Geoffroy Vellieux, 1, 2 Justine Frija-Masson, 1, 2 Anny Rouvel-Tallec, 1, 2 Xavier Drouot, 3 Marie-Pia d’Ortho 1, 2ġUniversité de Paris, NeuroDiderot, Inserm, Paris, F-75019, France 2Centre du sommeil, Service de Physiologie – Explorations Fonctionnelles, AP-HP, Hôpital Bichat-Claude Bernard, Paris, F-75018, France 3Neurophysiologie Clinique et Explorations Fonctionnelles, CHU de Poitiers, Poitiers, France
0 kommentar(er)
